A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib

Aymeric, Estelle; Bensignor, Emmanuel

doi:10.1111/vde.12458

Cited by 22 publications

(37 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Autoimmune subepidermal blistering dermatoses (ASBD) are uncommon diseases of animals and humans, which oclacitinib may be effective for the treatment of these diseases in dogs (Aymeric & Bensignor, 2017). Additional studies and clinical trials are needed to assess its use in the control of these diseases in dogs.…”

Section: Approved Jak Inhibitorsmentioning

confidence: 99%

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Hosseini

Gharibi

Marofi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small-molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases. K E Y W O R D S autoimmune diseases, cancer, Janus kinase inhibitors, novel treatment strategy

show abstract

Section: Approved Jak Inhibitorsmentioning

confidence: 99%

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Hosseini

Gharibi

Marofi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Beyond its approved use for treatment of canine pruritic and allergic skin diseases, oclacitinib has been shown to be beneficial for one dog with treatment refractory subepidermal blistering dermatosis, four dogs with idiopathic ear‐tip vasculitis, and two dogs with juvenile‐onset ischaemic dermatopathy; these are off‐label uses of this drug in the USA.…”

Section: Introductionmentioning

confidence: 99%

The role of oclacitinib in the management of ischaemic dermatopathy in four dogs

Levy

Linder

Olivry

2019

Veterinary Dermatology

View full text Add to dashboard Cite

Background -Ischaemic dermatopathy represents a heterogenous and poorly-characterized canine syndrome that is often refractory to conventional immunosuppression. Janus-kinase inhibitors (JAKinibs) are used for the treatment of various human autoimmune diseases, including dermatomyositis. Oclacitinib is a generally well-tolerated, veterinary-approved, nonselective JAKinib that has therapeutic potential as an immunosuppressant.Hypothesis/Objectives -To describe four cases of treatment refractory juvenile-onset ischaemic dermatopathy that rapidly and durably responded to oclacitinib administration.Animals -Four mixed-breed dogs, three 9-month-old male littermates and one 6-month-old female, were presented for generalized patchy alopecia, scarring and ulcerative dermatitis. Microscopic skin lesions were consistent with a severe ischaemic dermatopathy.Methods and materials -A complete remission of skin lesions could not be achieved in any dog with glucocorticoids alone, nor when these were combined with adjuvant immunosuppressants. Oclacitinib treatment was then initiated at the dosage of 0.4-0.7 mg/kg twice daily, along with a tapering regimen of oral prednisolone.Results -A full clinical remission was achieved within four weeks of starting this combination therapy, with prednisolone being stopped within eight weeks thereof. Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persistent twice daily administration of this JAKinib.Conclusions and clinical importance -Oclacitinib was a useful immunosuppressive adjuvant to oral glucocorticoids for the treatment of refractory or severe cases of ischaemic dermatopathy in these four dogs. Such observation warrants further studies of the safety, efficacy and mechanism of action of oclacitinib as an immunosuppressant.

show abstract

“…5 In dogs, the JAK inhibitor oclacitinib has been effective in controlling other immune-mediated diseases, including subepidermal blistering dermatoses, ischaemic dermatopathy and hyperkeratotic erythema multiforme. [6][7][8] The off-label use of oclacitinib in this case was based on these prior reports in other species, and the dose selected was based on a pharmacokinetic study in cats. 9 Oclacitinib's mechanism of action for successful treatment of this case is unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Janus kinase (JAK) inhibitors interfere with the intracellular signalling pathway of JAK‐STAT (Signal Transducer and Activator of Transcription) exerting a wide range of anti‐inflammatory and immunosuppressive effects. This class of drugs now is being used in alternative therapies for some neoplastic and immune‐mediated diseases in human beings and dogs 5–8 . This report describes the successful treatment of a cat with PF, using the JAK inhibitor oclacitinib (Apoquel, Zoetis; Madrid, Spain), which is registered for use in dogs with atopic dermatitis.…”

Section: Introductionmentioning

confidence: 99%

“…This class of drugs now is being used in alternative therapies for some neoplastic and immune-mediated diseases in human beings and dogs. [5][6][7][8] This report describes the successful treatment of a cat with PF, using the JAK inhibitor oclacitinib (Apoquel, Zoetis; Madrid, Spain), which is registered for use in dogs with atopic dermatitis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus

Carrasco

Martínez

Albinyana³

2021

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib

Abstract: The use of oclacitinib may be useful for the treatment of some autoimmune skin diseases in dogs. Further controlled studies are needed to confirm our findings.

Cited by 22 publications

References 18 publications

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

The role of oclacitinib in the management of ischaemic dermatopathy in four dogs

Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus

Contact Info

Product

Resources

About